JP2023546713A5 - - Google Patents

Info

Publication number
JP2023546713A5
JP2023546713A5 JP2023524833A JP2023524833A JP2023546713A5 JP 2023546713 A5 JP2023546713 A5 JP 2023546713A5 JP 2023524833 A JP2023524833 A JP 2023524833A JP 2023524833 A JP2023524833 A JP 2023524833A JP 2023546713 A5 JP2023546713 A5 JP 2023546713A5
Authority
JP
Japan
Prior art keywords
btla
ser
tyr
sequence
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056289 external-priority patent/WO2022087441A2/en
Publication of JP2023546713A publication Critical patent/JP2023546713A/ja
Publication of JP2023546713A5 publication Critical patent/JP2023546713A5/ja
Pending legal-status Critical Current

Links

JP2023524833A 2020-10-23 2021-10-22 Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 Pending JP2023546713A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105067P 2020-10-23 2020-10-23
US63/105,067 2020-10-23
US202163192984P 2021-05-25 2021-05-25
US63/192,984 2021-05-25
PCT/US2021/056289 WO2022087441A2 (en) 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (2)

Publication Number Publication Date
JP2023546713A JP2023546713A (ja) 2023-11-07
JP2023546713A5 true JP2023546713A5 (enExample) 2024-10-25

Family

ID=78695822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524833A Pending JP2023546713A (ja) 2020-10-23 2021-10-22 Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法

Country Status (9)

Country Link
US (1) US20230391872A1 (enExample)
EP (1) EP4232480A2 (enExample)
JP (1) JP2023546713A (enExample)
KR (1) KR20230096024A (enExample)
AU (1) AU2021365611A1 (enExample)
CA (1) CA3196493A1 (enExample)
IL (1) IL302135A (enExample)
MX (1) MX2023004633A (enExample)
WO (1) WO2022087441A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CN114585416B (zh) * 2019-04-01 2025-01-17 莱克制药股份有限公司 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same

Similar Documents

Publication Publication Date Title
RU2745898C2 (ru) Антитела, направленные против рецептора интерлейкина 36 (il-36r)
CN112409488B (zh) 针对多种冠状病毒的单克隆抗体及应用
HUE027760T2 (en) Soluble human ST-2 antibodies and assays
JP2018527952A (ja) 抗ｐｄ−１抗体及びその使用方法
US20240294655A1 (en) Antigen binding molecules that bind light
US10494430B2 (en) Anti-active GIP antibody
WO2020208150A1 (en) Protein binders for irhom2
CN110903393B (zh) 可结合IL6Rα的多肽及其应用
US20240084021A1 (en) Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) Anti-interleukin 36 receptor (il-36r) therapy for acne
US20230272092A1 (en) Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
CN106573059A (zh) 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
JP2025515337A5 (enExample)
WO2026032068A1 (zh) 一组chk36同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用
JP7796005B2 (ja) 抗ｔｒｅｍ－１抗体およびその使用
CN114276453A (zh) 可结合cd4的纳米抗体4nb334及其应用
IL302135A (en) B and t lymphocyte attenuator (btla) modulators and method of using same
CN120230210A (zh) 一组sh1同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用
JP7858057B2 (ja) Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子
CN113912720B (zh) 一种抗人bcma单克隆抗体及应用
CN110950956B (zh) 可结合pd1的多肽及其应用
CN114213539A (zh) 可结合cd4的纳米抗体4nb357及其应用
WO2022210830A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
WO2024050457A1 (en) Sars-cov-2 binding agents and uses thereof
RU2795625C2 (ru) Антигенсвязывающие белки против gitr и способы их применения